Definium’s latest Phase 3 topline results reinforced investor confidence in DT120 as the biotech described the dataset as its best to date for a pivotal depression program. The company said the trial showed strong improvements after a single dose and highlighted momentum from earlier efficacy signals as it works toward potential regulatory steps. The announcement arrives as the broader field watches for clarity on durability, safety tolerability, and whether effect sizes translate consistently across endpoints and patient subgroups. In late-stage depression, market expectations often hinge on reproducibility and clear differentiation on clinical scales. Definium’s positioning also illustrates how quickly capital flows can follow efficacy readouts in high-profile psychiatric pipelines—especially when timelines to regulatory submissions appear short. Next milestones for DT120 will likely include detailed endpoint breakdowns and safety reporting sufficient to support discussions on path-to-approval.